Genome-wide studies to identify risk factors for kidney disease with a focus on patients with diabetes

• Published in: Nephrology, dialysis, transplantation dialysis, transplantation, 2015-08, Vol.30 Suppl 4 (suppl 4), p.iv26-iv34
• Main Authors: Regele, Florina, Jelencsics, Kira, Shiffman, Dov, Paré, Guillaume, McQueen, Matthew J, Mann, Johannes F E, Oberbauer, Rainer
• Format: Article
• Language: English
• Subjects: Diabetes Mellitus - genetics; Diabetic Nephropathies - genetics; Genome-Wide Association Study; Humans; Polymorphism, Single Nucleotide; Renal Insufficiency, Chronic - genetics; Risk Factors
• ISSN: 0931-0509; 1460-2385
• DOI: 10.1093/ndt/gfv087

Chronic kidney disease (CKD) affects 10-13% of the general population and diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD). In addition to known demographic, biochemical and lifestyle risk factors, genetics is also contributing to CKD risk. In recent years, genome-wide association studies (GWAS) have provided a hypothesis-free approach to identify common genetic variants that could account for the genetic risk component of common diseases such as CKD. The identification of these variants might reveal the biological processes underlying renal impairment and could aid in improving risk estimates for CKD. This review aims to describe the methods as well as strengths and limitations of GWAS in CKD and to summarize the findings of recent GWAS in DN. Several loci and SNPs have been found to be associated with distinct CKD traits such as eGFR and albuminuria. For diabetic kidney disease, several loci were identified in different populations. Subsequent functional studies provided insights into the mechanism of action of some of these variants, such as UMOD or CERS2. However, overall, the results were ambiguous, and a few of the variants were not consistently replicated. In addition, the slow progression from albuminuria to ESRD could limit the power of longitudinal studies. The typically small effect size associated with genetic variants as well as the small portion of the variability of the phenotype explained by these variants limits the utility of genetic variants in improving risk prediction. Nevertheless, identifying these variants could give a deeper understanding of the molecular pathways underlying CKD, which in turn, could potentially lead to the development of new diagnostic and therapeutic tools.